Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pharvaris N.V.PHVS · Entity 4374 | Director | September 17, 2026 | September 21, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pharvaris N.V.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,167 |
Ending reported balance
After 2026-09-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-17 · Exercise / conversion · Acquired 35,000 · Balance 50,167 Row 2 · 2026-09-17 · Exercise / conversion · Acquired 17,500 · Balance 67,667 Row 3 · 2026-09-17 · Sale · Disposed 52,500 · Balance 15,167 F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.39 · Expires 2032-01-01 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-17 · Exercise / conversion · Disposed 35,000 · Balance 0 F2: 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.14 · Expires 2032-04-01 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-17 · Exercise / conversion · Disposed 17,500 · Balance 0 F3: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F2: 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
F3: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
ROCKET PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2026-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-02 · Purchase · Acquired 10,000 · Balance 50,000 F1: Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 19:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $18.14 | $0.00 |
DisclosureSEC source: 0001193125-26-396584 · ownership.xml · derivative · entry 5 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2032-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001193125-26-396584 · ownership.xml · derivative · entry 4 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2032-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 52,500 | $37.89 | $1,989,408.75 |
DisclosureSEC source: 0001193125-26-396584 · ownership.xml · nonDerivative · entry 3 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,167 F1 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $37.62 to $38.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 17,500 | $18.14 | $317,450.00 |
DisclosureSEC source: 0001193125-26-396584 · ownership.xml · nonDerivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 19:20 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 35,000 | $14.39 | $503,650.00 |
DisclosureSEC source: 0001193125-26-396584 · ownership.xml · nonDerivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 18:54 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001193125-26-236432 · ownership.xml · derivative · entry 3 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 21,000 shares Expires 2033-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F3 · derivative.exercise_date: 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. Read SEC document |
| May 20, 2026 Filed May 22, 2026 18:54 UTC | Pharvaris N.V. PHVS · Entity 4374 | SaleCommon Stock | 10,000 | $29.32 | $293,166.00 |
DisclosureSEC source: 0001193125-26-236432 · ownership.xml · nonDerivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,167 F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. F2 · price: The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $29.03 to $29.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2026 Filed May 22, 2026 18:54 UTC | Pharvaris N.V. PHVS · Entity 4374 | Exercise / conversionCommon Stock | 10,000 | $8.05 | $80,500.00 |
DisclosureSEC source: 0001193125-26-236432 · ownership.xml · nonDerivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise and sale from 10b5-1 trading plan. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | PurchaseCommon Stock | 10,000 | $3.44 | $34,400.00 |
DisclosureSEC source: 0001140361-26-000378 · form4.xml · nonDerivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · security: Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | PurchaseCommon Stock | 10,000 | $3.41 | $34,100.00 |
DisclosureSEC source: 0001140361-25-033017 · form4.xml · nonDerivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · security: Includes 30,000 restricted stock units ("RSUs") that convert to common stock on a one-for-one basis and vest in full on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jul 18, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026405 · form4.xml · nonDerivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · security: . Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: . Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| September 26, 2024 Filed Oct 29, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 607 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001140361-24-044548 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607 Underlying: Common Stock · 607 shares Expires 2034-09-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 607 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 3,325 | $15.04 Strike: $22.86 | $50,008.00 |
DisclosureSEC source: 0001140361-24-030731 · form4.xml · derivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,325 Underlying: Common Stock · 3,325 shares Expires 2034-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 3,325 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000. Read SEC document |
| June 13, 2024 Filed Jun 20, 2024 20:10 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 23,944 | $0.00 Strike: $22.86 | $0.00 |
DisclosureSEC source: 0001140361-24-030731 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,944 Underlying: Common Stock · 23,944 shares Expires 2034-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 3,590 | $13.93 Strike: $21.56 | $50,008.70 |
DisclosureSEC source: 0001140361-23-031526 · form4.xml · derivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,590 Underlying: Common Stock · 3,590 shares Expires 2033-06-22 F2 · derivative.exercise_date: This option represents a right to purchase a total of 3,590 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 23:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 25,850 | $0.00 Strike: $21.56 | $0.00 |
DisclosureSEC source: 0001140361-23-031526 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,850 Underlying: Common Stock · 25,850 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 7,345 | $6.80 Strike: $10.77 | $49,946.00 |
DisclosureSEC source: 0001140361-22-023149 · form4.xml · derivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,345 Underlying: Common Stock · 7,345 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 7,345 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000. Read SEC document |
| June 13, 2022 Filed Jun 16, 2022 01:07 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 47,745 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001140361-22-023149 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 Underlying: Common Stock · 47,745 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:55 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 1,699 | $29.42 Strike: $47.25 | $49,984.58 |
DisclosureSEC source: 0001140361-21-021291 · form4.xml · derivative · entry 2 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,699 Underlying: Common Stock · 1,699 shares Expires 2031-06-14 F2 · derivative.exercise_date: This option represents a right to purchase a total of 1,699 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. This option was issued to the Reporting Person in lieu of director retainer fees of $50,000. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:55 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 12,236 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001140361-21-021291 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,236 Underlying: Common Stock · 12,236 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,236 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022. Read SEC document |
| June 16, 2020 Filed Jun 19, 2020 01:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001140361-20-014238 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021 Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 23:14 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.50 | $0.00 |
DisclosureSEC source: 0001140361-20-009478 · form4.xml · derivative · entry 1 Bjork Elisabeth · CIK 0001810406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-04-20 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 1/3 of which shall vest on the first anniversary of the date of this grant and the remaining 2/3 of which shall vest in equal monthly installments over the subsequent two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.